Devicor touts FDA nod for its next-gen breast biopsy system

Fri, 12/14/2012 - 7:59am
Mass Device

The FDA approves Devicor's Mammotome revolve device, a less invasive dual vacuum-assisted biopsy system for sampling breast tissue.

Devicor logo

Cincinnati, Ohio-based Devicor landed FDA approval for its Mammotome revolve biopsy system, a next-generation biopsy system designed to provide high quality tissue specimens while improving the efficiency of pre-biopsy planning time.

The Mammotome system features specimen management for collecting and organizing high quality individual tissue samples in numbered, as well as specimen radiograph and pathology-ready chambers to preserve tissue integrity. The less invasive DualVac vacuum technology also helps clinicians secure larger contiguous tissue samples, according to the press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.